During the first quarter of 2012, the Company recognized revenue from installations of its PacBio RS systems, SMRT® cell and reagent consumables, instrument service contracts and grants. Revenue totaled
Gross loss for the first quarter totaled
Operating expenses comprised of research and development and selling, general and administrative expenses for the first quarter of 2012 totaled
Research and development expense during the first quarter of 2012 totaled
Cash and investments at
The Company’s system revenue backlog totaled approximately
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its First Quarter 2012 results today at
Forward-Looking Statements
This press release contains forward-looking statements relating to the Company’s operations and operating results, including statements relating to the Company’s revenue. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and that could materially affect actual results. Factors that could materially affect actual results can be found in
to update these forward-looking statements, except as required by law.
Unaudited Consolidated Statement of Operations (amounts in thousands, except per share amounts) |
|||
|
|||
|
Quarters Ended |
||
|
March 31, 2012 |
December 31, 2011 |
March 31, 2011 |
Revenue: |
|
|
|
Product revenue |
$ 8,715 |
$ 11,519 |
$ — |
Service and other revenue |
1,053 |
760 |
— |
Grant revenue |
270 |
165 |
270 |
Total revenue |
10,038 |
12,444 |
270 |
|
|
|
|
Cost of revenue: |
|
|
|
Cost of product revenue |
8,607 |
9,642 |
— |
Cost of service and other revenue |
1,583 |
1,265 |
— |
Total cost of revenue |
10,190 |
10,907 |
— |
Gross (loss) profit |
(152) |
1,537 |
270 |
|
|
|
|
Operating expense: |
|
|
|
Research and development |
12,073 |
12,415 |
24,118 |
Sales, general and administrative |
15,285 |
11,811 |
11,119 |
Total operating expense |
27,358 |
24,226 |
35,237 |
Operating loss |
(27,510) |
(22,689) |
(34,967) |
Other (expense) income, net |
(70) |
(134) |
158 |
Net loss |
$ (27,580) |
$ (22,823) |
$ (34,809) |
|
$ (0.50) |
$ (0.42) |
$ (0.66) |
Shares used in computing basic and diluted net loss per share |
55,201 |
54,861 |
52,756 |
Consolidated Balance Sheets (amounts in thousands) |
||
|
||
|
March 31, 2012 |
December 31, 2011 (1) |
|
(unaudited) |
|
Assets |
|
|
Cash and investments |
$ 161,349 |
$ 177,434 |
Accounts receivable |
1,505 |
4,557 |
Inventory |
11,821 |
15,517 |
Prepaid and other current assets |
2,131 |
2,093 |
Total current assets |
176,806 |
199,601 |
Property and equipment |
17,592 |
18,398 |
Other assets |
340 |
317 |
Total Assets |
$ 194,738 |
$ 218,316 |
|
|
|
Liabilities and Stockholders’ Equity |
|
|
Accounts payable |
$ 4,250 |
$ 4,742 |
Deferred revenue |
3,920 |
4,236 |
Accrued and other current liabilities |
11,626 |
10,398 |
Total current liabilities |
19,796 |
19,376 |
Facility financing and other non-current liabilities |
7,039 |
7,477 |
Stockholders’ equity |
167,903 |
191,463 |
|
|
|
Total Liabilities and Stockholders’ Equity |
$ 194,738 |
$ 218,316 |
|
||
Note 1: The consolidated balance sheet at December 31, 2011 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. |
CONTACT:Trevin Rard 650.521.8450 ir@pacificbiosciences.com
Source:
News Provided by Acquire Media